|
Jul 4
|
Declaration of shares and voting rights - Valneva SE - June 30, 2024
|
|
Jul 1
|
Valneva’s chikungunya vaccine gains EC’s market authorisation
|
|
Jul 1
|
Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ®
|
|
Jun 26
|
Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board
|
|
Jun 24
|
Valneva's (VALN) CHIKV Vaccine Gets Health Canada's Approval
|
|
Jun 24
|
Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®
|
|
May 21
|
Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
|
|
Jan 10
|
Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine
|
|
Dec 20
|
Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of Directors
|
|
Dec 6
|
VALNEVA Declaration of shares and voting rights - November 30, 2023
|
|
Dec 5
|
Pfizer, after delay, completes enrollment in Lyme vaccine trial
|
|
Dec 4
|
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15
|
|
Dec 4
|
Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®
|
|
Nov 27
|
EMA Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment
|
|
Sep 21
|
Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
|
|
Sep 7
|
UPDATE 1-Pfizer, Valneva say 'positive' result for Lyme disease vaccine candidate booster
|
|
Sep 7
|
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
|
|
Sep 6
|
VALNEVA Declaration of shares and voting rights: August 31, 2023
|